FASENRA® (Benralizumab) is an immunosuppressive drug that is used as an add-on maintenance therapy for patients with severe Eosinophilic Asthma.
FASENRA® is manufactured by AstraZeneca.
Administration and Dosage:
Administration of FASENRA® follows an induction regimen of 3 subcutaneous injections every 4 weeks followed by a maintenance injection, once every 8 weeks.
Common Side Effects:
The more common side effects of FASENRA® include allergic (hypersensitivity) reactions, including anaphylaxis.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
FASENRA® is indicated to treat:
- Add-on Maintenance for Severe Eosinophilic Asthma